Top

Published in:

25-06-2022 | Epstein-Barr Virus | Original Article

Maintenance of Epstein-Barr virus latency through interaction of LMP2A with CXCR4

Authors: Ni Qin, Yan Zhang, Lin Xu, Wen Liu, Bing Luo

Published in: Archives of Virology | Issue 10/2022

Abstract

Epstein-Barr virus (EBV) belongs to the subfamily Gammaherpesvirinae and was the first human tumor virus to be discovered. The global rate of EBV infection in adults exceeds 90%. EBV can participate in the regulation of multiple genes and signal pathways through its latency genes. Many studies have shown that CXCR4 is involved in the development of gastric cancer, but there have been few studies on the specific mechanisms involved in EBV-associated gastric cancer (EBVaGC). In this study, we explored the mechanism by which EBV-encoded products maintain latent EBV infection through interaction with CXCR4 and investigated the role of CXCR4 in EBV-positive cells. The results show that there is a positive feedback between the EBV-encoded products and CXCR4, and LMP2A can activate CXCR4 through the NF-κB pathway. In addition, CXCR4 can be fed back to LMP2A and EBNA1 through the ERK signaling pathway. At the same time, CXCR4 can promote the proliferation and migration of EBV-positive cells, reduce the expression of the immediate early protein BZLF1, the late protein EBV gp350, and the viral capsid antigen, and play an important role in maintaining the incubation period of EBV infection. These findings are applicable to the further targeted therapy of EBVaGC.

Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13:587–596. https://doi.org/10.1038/nm1567CrossRefPubMed

Cai J, Zhang Q, Qian X, Li J, Qi Q, Sun R, Han J, Zhu X, Xie M, Guo X, Xia R (2020) Extracellular ubiquitin promotes hepatoma metastasis by mediating M2 macrophage polarization via the activation of the CXCR4/ERK signaling pathway. Ann Transl Med 8:929. https://doi.org/10.21037/atm-20-1054CrossRefPubMedPubMedCentral

Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 22:469–480PubMed

Chatterjee S, Behnam Azad B, Nimmagadda S (2014) The intricate role of CXCR4 in cancer. Adv Cancer Res 124:31–82. https://doi.org/10.1016/b978-0-12-411638-2.00002-1CrossRefPubMedPubMedCentral

Gao H, Priebe W, Glod J, Banerjee D (2009) Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem cells (Dayton, Ohio) 27:857–865. https://doi.org/10.1002/stem.23CrossRef

Hamm HE (1998) The many faces of G protein signaling. J Biol Chem 273:669–672. https://doi.org/10.1074/jbc.273.2.669CrossRefPubMed

Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, Sakatani T, Takada K, Fukayama M (2008) Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res 68:1427–1435. https://doi.org/10.1158/0008-5472.Can-07-3027CrossRefPubMed

Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, Chang CH, Hsu HC, Fong YC, Tang CH (2009) Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol 221:204–212. https://doi.org/10.1002/jcp.21846CrossRefPubMed

Huo S, Luo Y, Deng R, Liu X, Wang J, Wang L, Zhang B, Wang F, Lu J, Li X (2020) EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells. J Immunother Cancer. https://doi.org/10.1136/jitc-2020-001588CrossRefPubMedPubMedCentral

10.

Kerr JR (2019) Epstein–Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol 72:651–658. https://doi.org/10.1136/jclinpath-2019-205822CrossRefPubMed

11.

Khare T, Bissonnette M, Khare S (2021) CXCL12-CXCR4/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies. Int J Mol Sci 22:1. https://doi.org/10.3390/ijms22147371CrossRef

12.

Kufareva I, Salanga CL, Handel TM (2015) Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol Cell Biol 93:372–383. https://doi.org/10.1038/icb.2015.15CrossRefPubMedPubMedCentral

13.

Li LN, Jiang KT, Tan P, Wang AH, Kong QY, Wang CY, Lu HR, Wang J (2015) Prognosis and clinicopathology of CXCR4 in colorectal cancer patients: a meta-analysis. Asian Pac J Cancer Prev 16:4077–4080. https://doi.org/10.7314/apjcp.2015.16.9.4077CrossRefPubMed

14.

Liu F, Yang B (2020) Double-targeted knockdown of miR-21 and CXCR4 inhibits malignant glioma progression by suppression of the PI3K/AKT and Raf/MEK/ERK pathways. Biomed Res Int 2020:7930160. https://doi.org/10.1155/2020/7930160CrossRefPubMedPubMedCentral

15.

Liu Y, Wei S, Zou Q, Luo Y (2018) Stachydrine suppresses viability and migration of astrocytoma cells via CXCR4/ERK and CXCR4/Akt pathway activity. Future Oncol (London, England) 14:1443–1459. https://doi.org/10.2217/fon-2017-0562CrossRef

16.

Longnecker R, Miller CL (1996) Regulation of Epstein–Barr virus latency by latent membrane protein 2. Trends Microbiol 4:38–42. https://doi.org/10.1016/0966-842x(96)81504-6CrossRefPubMed

17.

Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238:30–41. https://doi.org/10.1016/j.canlet.2005.06.021CrossRefPubMed

18.

Lv B, Yang X, Lv S, Wang L, Fan K, Shi R, Wang F, Song H, Ma X, Tan X, Xu K, Xie J, Wang G, Feng M, Zhang L (2015) CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in glioblastoma. Mol Neurobiol 52:1263–1268. https://doi.org/10.1007/s12035-014-8935-yCrossRefPubMed

19.

Majka M, Ratajczak J, Kowalska MA, Ratajczak MZ (2000) Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42/44 (MAPK), ELK-1 transcription factor and serine/threonine kinase AKT. Eur J Haematol 64:164–172. https://doi.org/10.1034/j.1600-0609.2000.90112.xCrossRefPubMed

20.

Münz C (2019) Latency and lytic replication in Epstein–Barr virus-associated oncogenesis. Nat Rev Microbiol 17:691–700. https://doi.org/10.1038/s41579-019-0249-7CrossRefPubMed

21.

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS (2009) Meta-analysis shows that prevalence of Epstein–Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137:824–833. https://doi.org/10.1053/j.gastro.2009.05.001CrossRefPubMed

22.

Saini V, Staren DM, Ziarek JJ, Nashaat ZN, Campbell EM, Volkman BF, Marchese A, Majetschak M (2011) The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions. J Biol Chem 286:33466–33477. https://doi.org/10.1074/jbc.M111.233742CrossRefPubMedPubMedCentral

23.

Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, Oupicky D (2017) Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol Ther 179:158–170. https://doi.org/10.1016/j.pharmthera.2017.05.012CrossRefPubMed

24.

Song ZY, Wang F, Cui SX, Qu XJ (2018) Knockdown of CXCR4 inhibits CXCL12-induced angiogenesis in HUVECs through downregulation of the MAPK/ERK and PI3K/AKT and the Wnt/β-catenin pathways. Cancer Investig 36:10–18. https://doi.org/10.1080/07357907.2017.1422512CrossRef

25.

Speck SH, Chatila T, Flemington E (1997) Reactivation of Epstein–Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol 5:399–405. https://doi.org/10.1016/s0966-842x(97)01129-3CrossRefPubMed

26.

Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, Taylor CM, Flemington EK (2013) Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 9:e1003341. https://doi.org/10.1371/journal.ppat.1003341CrossRefPubMedPubMedCentral

27.

Sun Y, Cheng Z, Ma L, Pei G (2002) Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 277:49212–49219. https://doi.org/10.1074/jbc.M207294200CrossRefPubMed

28.

Tang M, Yang Y, Yu J, Qiu J, Chen P, Wu Y, Wang Q, Xu Z, Ge J, Yu K, Zhuang J (2018) Tetramethylpyrazine in a murine alkali-burn model blocks NFκB/NRF-1/CXCR4-signaling-induced corneal neovascularization. Investig Ophthalmol Vis Sci 59:2133–2141. https://doi.org/10.1167/iovs.17-23712CrossRef

29.

Vila-Coro AJ, Rodríguez-Frade JM, Martín De Ana A, Moreno-Ortíz MC, Martínez AC, Mellado M (1999) The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 13:1699–1710CrossRef

30.

Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (New York, NY) 330:1066–1071. https://doi.org/10.1126/science.1194396CrossRef

31.

Xiao J, Lai H, Wei SH, Ye ZS, Gong FS, Chen LC (2019) lncRNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR4 and RhoA signaling pathway. Cancer Med 8:6768–6779. https://doi.org/10.1002/cam4.1302CrossRefPubMedPubMedCentral

32.

Xu G, Lu K, Shen M, Zhang Q, Pan W, Tang Z (2020) Correlation between chemokine CXCL-12 and ist receptor CXCR4 expression is associated with clinical prognosis of gastric cancer. Clin Lab. https://doi.org/10.7754/Clin.Lab.2019.190217CrossRefPubMed

33.

Xu J, Deng X, Tang M, Li L, Xiao L, Yang L, Zhong J, Bode AM, Dong Z, Tao Y, Cao Y (2013) Tyrosylprotein sulfotransferase-1 and tyrosine sulfation of chemokine receptor 4 are induced by Epstein–Barr virus encoded latent membrane protein 1 and associated with the metastatic potential of human nasopharyngeal carcinoma. PLoS One 8:e56114. https://doi.org/10.1371/journal.pone.0056114CrossRefPubMedPubMedCentral

34.

Yang J, Liu Z, Zeng B, Hu G, Gan R (2020) Epstein–Barr virus-associated gastric cancer: a distinct subtype. Cancer Lett 495:191–199. https://doi.org/10.1016/j.canlet.2020.09.019CrossRefPubMed

35.

Ye Q, Guo J, Chen Y, Cui Z, Chen Y (2021) Performance of plasma HSP90α, serum EBV VCA IgA antibody and plasma EBV DNA for the diagnosis and prognosis prediction of nasopharyngeal carcinoma. Cancer Manag Res 13:5793–5802. https://doi.org/10.2147/cmar.S320541CrossRefPubMedPubMedCentral

36.

Young LS, Murray PG (2003) Epstein–Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108–5121. https://doi.org/10.1038/sj.onc.1206556CrossRefPubMed

37.

Zhang Y, Liu W, Zhang W, Wang W, Song Y, Xiao H, Luo B (2019) Constitutive activation of the canonical NF-κB signaling pathway in EBV-associated gastric carcinoma. Virology 532:1–10. https://doi.org/10.1016/j.virol.2019.03.019CrossRefPubMed

Title: Maintenance of Epstein-Barr virus latency through interaction of LMP2A with CXCR4
Authors: Ni Qin
Yan Zhang
Lin Xu
Wen Liu
Bing Luo
Publication date: 25-06-2022
Publisher: Springer Vienna
Keywords: Epstein-Barr Virus
Gastric Cancer
Gastric Cancer
Published in: Archives of Virology / Issue 10/2022
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-022-05511-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2022

Complete sequence and genome characterization of a new potexvirus isolated from Chaenostoma cordatum

Complete genome analysis of a novel iflavirus from the spotted lanternfly Lycorma delicatula

Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2

Multiple isoforms of HSP70 and HSP90 required for betanodavirus multiplication in medaka cells

Role of the receptor for activated C kinase 1 during viral infection

Long-term protective immunity to goatpox in goats after a single immunization with a live attenuated goatpox vaccine

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials